<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3453">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623177</url>
  </required_header>
  <id_info>
    <org_study_id>RegCoVid-19</org_study_id>
    <nct_id>NCT04623177</nct_id>
  </id_info>
  <brief_title>Thromboprophylaxis for Patients in ICU With COVID-19</brief_title>
  <official_title>Effectiveness of Thromboprophylaxis With Low Molecular Weight Heparin in Critically Ill Patients With COVID-19. A Prospective, Cohort, Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Doctor Peset</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Sant Joan Despí Moisès Broggi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Navarrra Hospital (Clinica Universitaria)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Cruces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The respiratory distress that goes with COVID-19 infection has been related to a procoagulant&#xD;
      state, with thrombosis at both venous and arterial levels, that determines hypoxia and tissue&#xD;
      dysfunction at several organs. The main sign of this thrombotic activity seems to be the&#xD;
      D-Dimers, that have been proposed to identify patients with poor prognosis at an early stage.&#xD;
&#xD;
      Knowledge on how to prevent or even treat this procoagulant state is scarce. COVID-19&#xD;
      patients may be out of general thromboprophylaxis recommendations, and recent studies suggest&#xD;
      a better prognosis in severe COVID-19 patients receiving anticoagulant therapy with low&#xD;
      molecular weight heparin (LMWH). However, the LMWH efficacy and safety, mainly in patients&#xD;
      admitted to an Intensive Care Unit, remains to be validated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many reports have postulated a procoagulant state along with the respiratory distress caused&#xD;
      by coronavirus SARS-CoV2. A complex physiopathology has been proposed trying to explain this&#xD;
      profile, mainly based on the thromboinflammatory concept, with thrombosis at both venous and&#xD;
      arterial levels. Microvascular thrombi impair the blood flow all over the body, with a&#xD;
      vascular shunt due to capillary obstruction, that determines hypoxia and tissue dysfunction&#xD;
      at several organs, being the lung the more affected one.&#xD;
&#xD;
      Although D-Dimers (DD) are not specific indicators of clot formation, its elevation, in&#xD;
      combination with other parameters (hyperfibrinogenemia, mild thrombocytopenia) may suggest a&#xD;
      systemic coagulation activation with an increase of thrombin generation and fibrinolysis. In&#xD;
      fact, in a retrospective Chinese analysis, a DD higher than 1000 ng/ml was proposed to&#xD;
      identify patients with poor prognosis at an early stage.&#xD;
&#xD;
      Nevertheless, knowledge on how to prevent or even treat this procoagulant state is scarce.&#xD;
      Thromboprophylaxis with low molecular-weight heparin (LMWH) is recommended in most medical&#xD;
      patients admitted to the hospital and in nearly all patients in an Intensive Care Unit (ICU).&#xD;
      But COVID-19 patients may be out of these recommendations, and some treatment schemes has&#xD;
      been proposed, although how to decide the suitable LMWH for each clinical situation is&#xD;
      controversial. Recent retrospective studies suggest a better prognosis in severe COVID-19&#xD;
      patients receiving anticoagulant therapy with LMWH. However, the LMWH efficacy and safety,&#xD;
      mainly in COVID-19 patients admitted to the ICU, remains to be validated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>From admission to ICU discharge, an average of 1 month</time_frame>
    <description>Rate of mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU incidence of thrombotic events</measure>
    <time_frame>From admission to ICU discharge, an average of 1 month</time_frame>
    <description>A composite endpoint to evaluate efficacy made up of: myocardial infarction, stroke, incidental pulmonary thromboembolism, pulmonary thromboembolism with worsening of hypoxemia, Pulmonary thromboembolism with hemodynamic repercussion, other venous thromboses without pulmonary thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU incidence of bleeding events</measure>
    <time_frame>From admission to ICU discharge, an average of 1 month</time_frame>
    <description>Composite endpoint to evaluate safety made up of: bleeding needing transfusion, bleeding wit hemodynamic repercussion, other bleeding (minor bleeding)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>From admission to ICU discharge, an average of 1 month</time_frame>
    <description>Days admitted in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of invasive mechanical ventilation</measure>
    <time_frame>From admission to ICU discharge, an average of 1 month</time_frame>
    <description>Days treated with invasive mechanical ventilation (controlled or assisted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LMWH in other parameters</measure>
    <time_frame>From admission to ICU discharge, an average of 1 month</time_frame>
    <description>Description of the relationship if any between the use of LMWH and thrombotic or inflammatory parameters (D-Dimer levels, ferritin) or lung dead space</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Covid19</condition>
  <condition>Anticoagulant Therapy</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <description>Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thromboprophylaxis</arm_group_label>
    <description>Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No heparin</arm_group_label>
    <description>Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive COVID-19 patients admitted to participating ICUs from March 12th to&#xD;
        September 1st were included if they fulfill the inclusion criteria and present no exclusion&#xD;
        criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed SARS-CoV2 infection from a respiratory tract sample using a polymerase chain&#xD;
             reaction assay.&#xD;
&#xD;
          -  Admitted to ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-confirmed SARS-CoV2 infection&#xD;
&#xD;
          -  No data at first day ICU admission&#xD;
&#xD;
          -  Patient with do-not resuscitate orders&#xD;
&#xD;
          -  Patient who did not meet the outcomes of death or ICU discharge by the time of study&#xD;
             completion date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raquel Ferrandis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <state>Castilla La Mancha</state>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <state>Castilla Y León</state>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rio Ortega</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla Y León</state>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrasa</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>8227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>3550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Cáceres</name>
      <address>
        <city>Cáceres</city>
        <state>Extramedura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ferrol</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Povisa</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas</city>
        <state>Gran Canaria</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Araba</name>
      <address>
        <city>Álava</city>
        <state>País Vasco</state>
        <zip>1009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas Cima</name>
      <address>
        <city>Barcelona</city>
        <zip>8034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan Despí</name>
      <address>
        <city>Barcelona</city>
        <zip>8970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofia</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rafael Méndez</name>
      <address>
        <city>Murcia</city>
        <zip>30817</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. Review.</citation>
    <PMID>32311448</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019 Feb 28;133(9):906-918. doi: 10.1182/blood-2018-11-882993. Epub 2019 Jan 14. Review.</citation>
    <PMID>30642917</PMID>
  </reference>
  <reference>
    <citation>Ferrandis R, Llau JV, Quintana M, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A. COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients? Crit Care. 2020 Jun 11;24(1):332. doi: 10.1186/s13054-020-03052-9.</citation>
    <PMID>32527286</PMID>
  </reference>
  <reference>
    <citation>Llau JV, Ferrandis R, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A, Quintana M, Amezaga R, Gero M, Serrano A, Marcos P. SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection. Rev Esp Anestesiol Reanim. 2020 Aug - Sep;67(7):391-399. doi: 10.1016/j.redar.2020.05.007. Epub 2020 May 23. English, Spanish.</citation>
    <PMID>32591185</PMID>
  </reference>
  <reference>
    <citation>Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020 Jul 7;76(1):122-124. doi: 10.1016/j.jacc.2020.05.001. Epub 2020 May 6.</citation>
    <PMID>32387623</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Tang N, Bai H, Xiong D, Sun Z. Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. J Thromb Haemost. 2020 Sep;18(9):2428-2430. doi: 10.1111/jth.14988.</citation>
    <PMID>32619329</PMID>
  </reference>
  <reference>
    <citation>Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.</citation>
    <PMID>32220112</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Low Molecular weight heparin</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Anticoagulant treatment</keyword>
  <keyword>Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

